C. Popa (Bucuresti (Sector 5), Romania), G. Günther (Bremgarten bei Bern, Switzerland)
The use of the lytic D29 mycobacteriophages for accelerated determination of the drug sensitivity of tuberculosis mycobacteria to first and second-line anti-TB drugs in clinical isolates obtained after initial cultivation
M. Vladimirsky (Moscow, Russian Federation), M. Lapenkova (Moscow, Russian Federation), Y. Alyapkina (Moscow, Russian Federation), I. Vasilyeva (Moscow, Russian Federation), G. Arustamova (Moscow, Russian Federation), P. Philippov (Moscow, Russian Federation)
|     |
Genomic factors associated with katG-S315T in Mycobacterium tuberculosis clinical isolates in Vietnam
N. Hang (Hanoi, Vietnam), M. Hijikata (Tokyo, Japan), S. Maeda (Hokkaido, Japan), A. Miyabayashi (Tokyo, Japan), S. Seto (Tokyo, Japan), N. Diem (Da Nang, Vietnam), N. Yen (Da Nang, Vietnam), P. Thuong (Hanoi, Vietnam), H. Huan (Hanoi, Vietnam), N. Hoang (Hanoi, Vietnam), S. Mitarai (Tokyo, Japan), S. Kato (Tokyo, Japan), N. Keicho (Tokyo, Japan)
| |
Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors
K. Fujita (Kyoto, Japan), Y. Yamamoto (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan)
| |
Ready steady spit: A community based screening for lung tuberculosis amongst high-risk groups in Aalborg, Denmark
S. Shakar (Aalborg, Denmark), N. Stærke (Aarhus, Denmark), M. Christensen (Aalborg, Denmark), U. Weinreich (Aalborg, Denmark)
| |
Mortality and associated factors among drug-resistant tuberculosis patients in Portugal, 2000-2016
O. Oliveira (Viseu, Portugal), R. Gaio (Porto, Portugal), T. Rito (Braga, Portugal), M. Correia-Neves (Braga, Portugal), R. Duarte (Porto, Portugal)
| |
Role of N-acetylcysteine(NAC) in preventing development of anti tuberculosis therapy(ATT) induced liver injury in pulmonary tuberculosis(PTB) patients, a simple randomized single blind clinical trial
S. Ahmed (Karachi, Pakistan), N. Ahmed Rao (Karachi, Pakistan)
| |
IP-10 decreases during antituberculous treatment in children with active tuberculosis.
A. Strzelak (Warszawa, Poland), A. Komorowska-Piotrowska (Warszawa, Poland), A. Borowa (Otwock, Poland), M. Krasinska (Otwock, Poland), W. Feleszko (Warszawa, Poland), M. Kulus (Warszawa, Poland)
| |